FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152211177> ?p ?o ?g. }

• W2152211177 endingPage "1353" @default.
• W2152211177 startingPage "1341" @default.
• W2152211177 abstract "PURPOSE It is known that over expression of IL6 in prostate cancer cells confer enzalutamide resistance and that this may occur through constitutive Stat3 activation. Additionally, recent pre-clinical studies suggested enzalutamide might have the potential adverse effect of inducing metastasis of prostate cancer cells via Stat3 activation. This study is aimed to target Stat3 activation and improve enzalutamide therapy. EXPERIMENTAL DESIGN Sensitivity of prostate cancer cells to enzalutamide was tested using cell growth assays and clonogenic assays. Wound healing and invasion assays were performed to determine cell migration and invasion in vitro. Quantitative reverse transcription-PCR, ELISA and Western blotting were performed to detect expression levels of PSA, c-Myc, survivin, Stat3, and AR. ChIP assay was performed to examine recruitment of AR to the PSA promoter. RESULTS In the present study, we found niclosamide, a previously identified novel inhibitor of androgen receptor variant (AR-V7), inhibited Stat3 phosphorylation, and expression of downstream target genes. Niclosamide synergistically reversed enzalutamide resistance in prostate cancer cells and combination treatment of niclosamide with enzalutamide significantly induced cell apoptosis and inhibited cell growth, colony formation, cell migration and invasion. Knock down of Stat3 abrogated enzalutamide resistance resulting in reduced recruitment of AR to the PSA promoter in prostate cancer cells expressing IL6. Moreover, niclosamide reversed enzalutamide resistance by down-regulating Stat3 target gene expression Stat3and abrogating recruitment of AR to PSA promoter resulting in PSA inhibition. CONCLUSIONS This study demonstrated the IL6-Stat3-AR axis in prostate cancer is one of the crucial mechanisms of enzalutamide resistance. Niclosamide has the potential to target the IL6-Stat3-AR pathway to overcome enzalutamide resistance and inhibit migration and invasion in advanced prostate cancer. Prostate 75:1341–1353, 2015. © 2015 Wiley Periodicals, Inc." @default.
• W2152211177 created "2016-06-24" @default.
• W2152211177 creator A5012734277 @default.
• W2152211177 creator A5016060924 @default.
• W2152211177 creator A5028546502 @default.
• W2152211177 creator A5048369552 @default.
• W2152211177 creator A5087359161 @default.
• W2152211177 creator A5088621070 @default.
• W2152211177 date "2015-05-13" @default.
• W2152211177 modified "2023-10-17" @default.
• W2152211177 title "Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition" @default.
• W2152211177 cites W1536812836 @default.
• W2152211177 cites W1757111527 @default.
• W2152211177 cites W1968064237 @default.
• W2152211177 cites W1968365367 @default.
• W2152211177 cites W1968855063 @default.
• W2152211177 cites W1969241521 @default.
• W2152211177 cites W1970345836 @default.
• W2152211177 cites W1973442219 @default.
• W2152211177 cites W1981467511 @default.
• W2152211177 cites W2006382528 @default.
• W2152211177 cites W2010072924 @default.
• W2152211177 cites W2014556566 @default.
• W2152211177 cites W2017715430 @default.
• W2152211177 cites W2017919614 @default.
• W2152211177 cites W2021536610 @default.
• W2152211177 cites W2042756500 @default.
• W2152211177 cites W2054378536 @default.
• W2152211177 cites W2069749649 @default.
• W2152211177 cites W2088357471 @default.
• W2152211177 cites W2096795721 @default.
• W2152211177 cites W2102969047 @default.
• W2152211177 cites W2111791735 @default.
• W2152211177 cites W2118428599 @default.
• W2152211177 cites W2126373871 @default.
• W2152211177 cites W2127342790 @default.
• W2152211177 cites W2133059565 @default.
• W2152211177 cites W2137657375 @default.
• W2152211177 cites W2138640102 @default.
• W2152211177 cites W2139216034 @default.
• W2152211177 cites W2148643283 @default.
• W2152211177 cites W2151701050 @default.
• W2152211177 cites W2166918329 @default.
• W2152211177 cites W2170647183 @default.
• W2152211177 cites W2783142245 @default.
• W2152211177 doi "https://doi.org/10.1002/pros.23015" @default.
• W2152211177 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4536195" @default.
• W2152211177 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25970160" @default.
• W2152211177 hasPublicationYear "2015" @default.
• W2152211177 type Work @default.
• W2152211177 sameAs 2152211177 @default.
• W2152211177 citedByCount "81" @default.
• W2152211177 countsByYear W21522111772015 @default.
• W2152211177 countsByYear W21522111772016 @default.
• W2152211177 countsByYear W21522111772017 @default.
• W2152211177 countsByYear W21522111772018 @default.
• W2152211177 countsByYear W21522111772019 @default.
• W2152211177 countsByYear W21522111772020 @default.
• W2152211177 countsByYear W21522111772021 @default.
• W2152211177 countsByYear W21522111772022 @default.
• W2152211177 countsByYear W21522111772023 @default.
• W2152211177 crossrefType "journal-article" @default.
• W2152211177 hasAuthorship W2152211177A5012734277 @default.
• W2152211177 hasAuthorship W2152211177A5016060924 @default.
• W2152211177 hasAuthorship W2152211177A5028546502 @default.
• W2152211177 hasAuthorship W2152211177A5048369552 @default.
• W2152211177 hasAuthorship W2152211177A5087359161 @default.
• W2152211177 hasAuthorship W2152211177A5088621070 @default.
• W2152211177 hasBestOaLocation W21522111772 @default.
• W2152211177 hasConcept C121608353 @default.
• W2152211177 hasConcept C126322002 @default.
• W2152211177 hasConcept C18903297 @default.
• W2152211177 hasConcept C2775975398 @default.
• W2152211177 hasConcept C2776306103 @default.
• W2152211177 hasConcept C2776551883 @default.
• W2152211177 hasConcept C2780192828 @default.
• W2152211177 hasConcept C502942594 @default.
• W2152211177 hasConcept C54355233 @default.
• W2152211177 hasConcept C61367390 @default.
• W2152211177 hasConcept C62112901 @default.
• W2152211177 hasConcept C71924100 @default.
• W2152211177 hasConcept C86803240 @default.
• W2152211177 hasConcept C96232424 @default.
• W2152211177 hasConceptScore W2152211177C121608353 @default.
• W2152211177 hasConceptScore W2152211177C126322002 @default.
• W2152211177 hasConceptScore W2152211177C18903297 @default.
• W2152211177 hasConceptScore W2152211177C2775975398 @default.
• W2152211177 hasConceptScore W2152211177C2776306103 @default.
• W2152211177 hasConceptScore W2152211177C2776551883 @default.
• W2152211177 hasConceptScore W2152211177C2780192828 @default.
• W2152211177 hasConceptScore W2152211177C502942594 @default.
• W2152211177 hasConceptScore W2152211177C54355233 @default.
• W2152211177 hasConceptScore W2152211177C61367390 @default.
• W2152211177 hasConceptScore W2152211177C62112901 @default.
• W2152211177 hasConceptScore W2152211177C71924100 @default.
• W2152211177 hasConceptScore W2152211177C86803240 @default.
• W2152211177 hasConceptScore W2152211177C96232424 @default.
• W2152211177 hasIssue "13" @default.

• next